Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC

Detection of non-reciprocal/reciprocal ALK translocation as poor predictive marker in first-line crizotinib-treated ALK-rearranged non-small cell lung cancer patients

(2020) Yongchang Zhang et al.   Journal of Thoracic Oncology

Identification of Novel CD74-NRG2α Fusion From Comprehensive Profiling of Lung Adenocarcinoma in Japanese Never or Light Smokers

(2020) Shinji Kohsaka et al.   Journal of Thoracic Oncology

Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing

(2020) Danielle Cohen et al.   Journal of Thoracic Oncology

Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in non-small cell lung cancer

(2020) Weihua Li et al.   Journal of Thoracic Oncology

Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer

(2020) Alice Indini et al.   EXPERT OPINION ON PHARMACOTHERAPY

Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants

(2020) Haiyan Xu et al.   Cancer Medicine

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer

(2020) J.J. Lin et al.   ANNALS OF ONCOLOGY

Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study

(2020) Jing Zheng et al.   LUNG CANCER

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

(2020) Lori J. Wirth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK -rearranged non-small-cell lung cancer

(2019) Peng Song et al.   Cancer Medicine

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

(2019) A T Shaw et al.   ANNALS OF ONCOLOGY

High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden

(2019) Ryma Benayed et al.   CLINICAL CANCER RESEARCH

Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms

(2019) James P. Solomon et al.   CANCER RESEARCH

Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to Crizotinib

(2019) Bao-Dong Qin et al.   Journal of Thoracic Oncology

Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient with Microsatellite-Instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report

(2019) Yi Zhang et al.   Clinical Lung Cancer

Simultaneous Detection of Gene Fusions and Base Mutations in Cancer Tissue Biopsies by Sequencing Dual Nucleic Acid Templates in Unified Reaction

(2019) Zhengbo Song et al.   CLINICAL CHEMISTRY

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

(2019) Alice T Shaw et al.   LANCET ONCOLOGY

Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer

(2018) Eric K Singhi et al.   Future Oncology

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

(2018) Jessica J. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

VIT - ALK , a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma

(2018) Song Hu et al.   Journal of Thoracic Oncology

Efficacy of Crizotinib among Different Types of  ROS1 Fusion Partners in Patients with ROS1 -Rearranged Non–Small Cell Lung Cancer

(2018) Ziming Li et al.   Journal of Thoracic Oncology

Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples

(2018) Kurtis D. Davies et al.   Journal of Thoracic Oncology

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

(2018) Neal I. Lindeman et al.   Journal of Thoracic Oncology

Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants

(2018) Yan Li et al.   LUNG CANCER

Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer

(2018) Jason N Rosenbaum et al.   MODERN PATHOLOGY

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

(2018) D. Ross Camidge et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of a novel WNK1–ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib

(2018) Yutao Liu et al.   LUNG CANCER

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

(2018) Alexander Drilon et al.   Cancer Discovery

A Novel CAMKMT Exon3-ALK Exon20 Fusion Variant was Identified in a Primary Pulmonary Mucinous Adenocarcinoma

(2018) Xueting Hu et al.   Journal of Thoracic Oncology

TBC1D32-RET: A Novel RET Oncogenic Fusion in Lung Adenocarcinoma

(2018) Panli Peng et al.   Journal of Thoracic Oncology

Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment

(2017) Wenbin Li et al.   Journal of Thoracic Oncology

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

(2017) Kiyotaka Yoh et al.   Lancet Respiratory Medicine

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

(2016) Tatsuya Yoshida et al.   JOURNAL OF CLINICAL ONCOLOGY

BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib

(2015) Ling Shan et al.   Journal of Thoracic Oncology

A Novel Mechanism of EML4-ALK Rearrangement Mediated by Chromothripsis in a Patient-Derived Cell Line

(2014) Tatsushi Kodama et al.   Journal of Thoracic Oncology

Fusion genes and their discovery using high throughput sequencing

(2013) M.J. Annala et al.   CANCER LETTERS

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration

(2012) H. Thorvaldsdottir et al.   BRIEFINGS IN BIOINFORMATICS

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

RET, ROS1 and ALK fusions in lung cancer

(2012) Kengo Takeuchi et al.   NATURE MEDICINE

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome

(2009) Ben Langmead et al.   GENOME BIOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER